How Many Corcept Therapeutics Incorporated (NASDAQ:CORT)’s Analysts Are Bearish?

January 22, 2018 - By Winifred Garcia

 How Many Corcept Therapeutics Incorporated (NASDAQ:CORT)'s Analysts Are Bearish?
Investors sentiment decreased to 1.96 in Q3 2017. Its down 0.47, from 2.43 in 2017Q2. It worsened, as 13 investors sold Corcept Therapeutics Incorporated shares while 39 reduced holdings. 47 funds opened positions while 55 raised stakes. 71.96 million shares or 6.38% more from 67.64 million shares in 2017Q2 were reported.
Birchview Cap Limited Partnership reported 95,000 shares stake. Cambridge Tru has invested 0.05% in Corcept Therapeutics Incorporated (NASDAQ:CORT). First Tru Lp has 0.01% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT). Bogle Invest Mgmt Lp De reported 0.91% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). Paloma Ptnrs Mgmt holds 0.02% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 62,439 shares. Prudential accumulated 1.10M shares. Bridgeway Capital Mgmt Inc has 0.01% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 37,800 shares. Blume Mgmt has 0.01% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 700 shares. Citadel Advsr Ltd Com holds 0% or 131,836 shares in its portfolio. Jasper Ridge Prtnrs Ltd Partnership invested in 0.01% or 10,000 shares. Ameritas Investment Prtnrs owns 8,001 shares. Raymond James And Associates stated it has 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Advisory, a Illinois-based fund reported 51,025 shares. Hillsdale Invest Mngmt Incorporated holds 0.29% or 90,300 shares. Ami Asset Mgmt owns 527,515 shares for 0.72% of their portfolio.

Since December 8, 2017, it had 0 insider purchases, and 2 selling transactions for $283,125 activity.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Ratings Coverage

Among 4 analysts covering Corcept Therapeutics (NASDAQ:CORT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corcept Therapeutics had 7 analyst reports since February 2, 2017 according to SRatingsIntel. Stifel Nicolaus maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) on Friday, November 3 with “Buy” rating. As per Thursday, February 2, the company rating was initiated by Ladenburg Thalmann. Piper Jaffray maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) on Thursday, August 24 with “Buy” rating. The firm has “Buy” rating given on Wednesday, October 11 by Piper Jaffray. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) has “Buy” rating given on Friday, September 8 by Piper Jaffray. Below is a list of Corcept Therapeutics Incorporated (NASDAQ:CORT) latest ratings and price target changes.

03/11/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $25.0 Maintain
11/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $24.0 Maintain
08/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $24.0 Maintain
31/08/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $20 Initiates Coverage On
24/08/2017 Broker: Piper Jaffray Rating: Buy New Target: $18.0 Maintain

The stock increased 2.67% or $0.64 during the last trading session, reaching $24.62. About 1.89 million shares traded or 2.57% up from the average. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 124.81% since January 22, 2017 and is uptrending. It has outperformed by 108.11% the S&P500.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company has market cap of $2.81 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It has a 84.9 P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: